Company intelligence / Profile preview
ImmunoGenesis
Houston, Texas, United Statesimmunogenesis.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
ImmunoGenesis has initiated a Phase 1a/1b study of its lead compound IMGS‑001, a novel dual-specific PD‑L1/PD‑L2 antibody with killing function for immune-excluded, cold tumors. Preliminary data from this trial are being collected. The company has also started a Phase 2 trial for IMGS‑101 (evofosfamide), a hypoxia reversal agent studied in combination with checkpoint inhibition[4].
Preclinical studies suggest that IMGS‑001 could increase monotherapy response rates in cold tumors by more than fivefold compared to current PD‑1 pathway inhibitors[1]. IMGS‑101 has been studied extensively (>1600 patients) and aims to reverse immune resistance in hypoxic solid tumors[1].
The company’s approach focuses on overcoming immune resistance mechanisms that make “cold” tumors unresponsive to existing immunotherapies.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Chemotherapeutic prodrugsSTING agonists4‑1BB antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
MD Anderson Cancer Center (licensing of key development assets including dual-specific mAbs, STING agonists, and 4–1BB antibodies)[2]
Beyond the preview
Go deeper on ImmunoGenesis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoGenesis.